KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel ima edilen olasılık
Evet 79%
Piyasa kalitesi
43 / 100
Düşük kalite24s Hacim
—
Likidite
₺24,6 B
Düşük likiditeAlış / Satış
78.0% / 84.0%
Spread
6.0 pt
Geniş spreadPiyasa verileri
2 dakika önce güncellendi
17 Haz 26 21:00 UTC1 Oca 27 04:59 UTC
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiEbola pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketNew pandemic in 2026?
PolymarketKurallar
If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Uzlaşma kaynağı:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact.
- It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme.
- Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.
Açık piyasalar
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Toplam Hacim
- ₺876,3 Mn
- 24s Hacim
- ₺1 Mn
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Toplam Hacim
- ₺91,4 Mn
- 24s Hacim
- ₺291,7 B
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 daha fazla sonuç
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Toplam Hacim
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Toplam Hacim
- ₺51,6 Mn
- 24s Hacim
- ₺85,3 B
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+1.0pt60%
+2 daha fazla sonuç
- Toplam Hacim
- ₺48,6 Mn
- 24s Hacim
- ₺58,5 B
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Sık sorulan sorular
- FDA decision: Venglustat by Sanofi (in 2026) için güncel oranlar nedir?
- Kalshi, 8 Eylül 2026 itibarıyla Yes için 79% fiyatlıyor.
- FDA decision: Venglustat by Sanofi (in 2026) ne zaman sonuçlanacak?
- FDA decision: Venglustat by Sanofi (in 2026) için öngörülen sonuçlanma tarihi 1 Ocak 2027.
- FDA decision: Venglustat by Sanofi (in 2026) nasıl sonuçlandırılıyor?
- Kalshi bu piyasayı şu şekilde sonuçlandırır: If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.